Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919470 | 1.00 | NFKB1 (0.33) | NFKB1NFKB2RELAGAAUSP2 | |
| SCHEMBL17190433 | 0.92 | NFKB1 (0.31) | NFKB1NFKB2RELA | |
| SCHEMBL18449784 | 0.84 | CA12 (0.31) | — | |
| SCHEMBL18488392 | 0.81 | CA12 (0.31) | — | |
| SCHEMBL17190429 | 0.81 | — | — | |
| SCHEMBL18024846 | 0.81 | — | — | |
| SCHEMBL8512237 | 0.78 | CA12 (0.42) | — | |
| SCHEMBL18555563 | 0.78 | CA12 (0.42) | — | |
| SCHEMBL30873268 | 0.78 | CA12 (0.42) | — | |
| SCHEMBL8512235 | 0.78 | CA12 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187706-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230020161-A1 | Tricyclic Modulators of PP2A | RAPPTA THERAPEUTICS OY (FI) | 2023-01-19 | — | — | US | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-10-22 | — | — | US | disclosed |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-05 | — | — | US | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NFKB1 61/4885NFKB2 65/4885RELA 117/4885 |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | NFKB1 1016/4885NFKB2 806/4885RELA 155/4885 |
| US-12187706-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NFKB1 61/4885NFKB2 65/4885RELA 117/4885 |
| US-20230020161-A1 | Tricyclic Modulators of PP2A | PPP2CA, PPP4C, PPP3R1 | NFKB1 882/4885NFKB2 689/4885RELA 703/4885 |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | DDT, ODC1, CBR1 | NFKB1 3716/4885NFKB2 3309/4885RELA 4160/4885 |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | NFKB1 1016/4885NFKB2 806/4885RELA 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.